Age: 55.0
Sex: M
Vaccine: COVID19
Symptoms: COVID-19, SARS-CoV-2 test
Clinical narrative: Tested pos May 3rd.; This spontaneous case was reported by a patient and describes the occurrence of COVID-19 (Tested pos May 3rd.) in a 55-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Patient do not have any relevant medical history and concurrent conditions.  Concurrent medical conditions included Drug allergy.    On 02-May-2022 at 12:30 PM, the patient received fourth dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 03-May-2022,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced COVID-19 (Tested pos May 3rd.). The patient was treated with NIRMATRELVIR, RITONAVIR (PAXLOVID) from 03-May-2022 to 08-May-2022 for COVID-19, at an unspecified dose and frequency. At the time of the report, COVID-19 (Tested pos May 3rd.) had not resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 03-May-2022, SARS-CoV-2 test: positive (Positive) Positive. In May 2022, SARS-CoV-2 test: negative (Negative) Negative and. On 15-May-2022, SARS-CoV-2 test positive (Positive) Positive.         It was reported that, the patient received 4th dose on 02-May-2022 and was tested positive on 03-May-2022. The patient began Paxlovid from 03-May-2022 to 08-May-2022 and was tested negative. On 15-May-2022, the patient was tested positive again.  Company Comment: This spontaneous case concerns a 55-year-old, male patient with no relevant medical history who experienced the unexpected, non-serious adverse event of special interest of COVID-19 (with a positive SARS-CoV-2 test) which occurred one day after receiving the fourth dose of mRNA-1273 vaccine. No information was provided regarding the first three doses of COVID 19 vaccination. Patient tested positive for COVID-19 one day after vaccine administration. The type of test and associated signs and symptoms were not reported. He tested negative for COVID-19 after treatment with unspecified dose and frequency of Nirmatrelvir, Ritonavir (Paxlovid) taken for six days. However, he tested positive again for COVID-19 12 days after the onset of the event. The clinical course and findings of clinical investigations were not provided in this report. The benefit-risk relationship of mRNA-1273 is not affected by this report.; Sender's Comments: This spontaneous case concerns a 55-year-old, male patient with no relevant medical history who experienced the unexpected, non-serious adverse event of special interest of COVID-19 (with a positive SARS-CoV-2 test) which occurred one day after receiving the fourth dose of mRNA-1273 vaccine. No information was provided regarding the first three doses of COVID 19 vaccination. Patient tested positive for COVID-19 one day after vaccine administration. The type of test and associated signs and symptoms were not reported. He tested negative for COVID-19 after treatment with unspecified dose and frequency of Nirmatrelvir, Ritonavir (Paxlovid) taken for six days. However, he tested positive again for COVID-19 12 days after the onset of the event. The clinical course and findings of clinical investigations were not provided in this report. The benefit-risk relationship of mRNA-1273 is not affected by this report.